SCHEMBL11945104

SCHEMBL11945104

CC(Oc1c(N2CCN(S(=O)(=O)Cc3ccccc3)CC2)cnn(-c2ccccc2)c1=O)c1ccccn1

nearest known ligand 0.51

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 4/20 0.51
▸ ALDH1A1 P00352 6/20 0.45
▸ DCTPP1 Q9H773 2/20 0.45
▸ HSD11B1 P28845 1/20 0.40
▸ SMN1; SMN2 Q16637 2/20 0.39
▸ LMNA P02545 2/20 0.39
▸ POLB P06746 1/20 0.39
▸ KMT2A Q03164 1/20 0.39
▸ CA12 O43570 1/20 0.39
▸ CA1 P00915 1/20 0.39
▸ CA2 P00918 1/20 0.39
▸ CA9 Q16790 1/20 0.39
▸ NPC1 O15118 2/20 0.37
▸ RAB9A P51151 2/20 0.37
▸ RXFP1 Q9HBX9 1/20 0.37
▸ KDM4E B2RXH2 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11943981 0.88 ALDH1A1 (0.48) MAPTALDH1A1DCTPP1SMN1; SMN2LMNA
SCHEMBL11945105 0.87 ALDH1A1 (0.47) MAPTALDH1A1DCTPP1SMN1; SMN2LMNA
SCHEMBL11943947 0.85 MAPT (0.52) MAPTALDH1A1DCTPP1SMN1; SMN2LMNA
SCHEMBL11944240 0.83 MAPT (0.61) MAPTALDH1A1DCTPP1SMN1; SMN2LMNA
SCHEMBL11945052 0.83 MAPT (0.61) MAPTALDH1A1DCTPP1SMN1; SMN2LMNA
SCHEMBL11943928 0.82 MAPT (0.52) MAPTALDH1A1DCTPP1HSD11B1SMN1; SMN2
SCHEMBL11944120 0.82 MAPT (0.54) MAPTALDH1A1DCTPP1SMN1; SMN2LMNA
SCHEMBL11945086 0.82 MAPT (0.54) MAPTALDH1A1DCTPP1SMN1; SMN2LMNA
SCHEMBL11944410 0.82 MAPT (0.57) MAPTALDH1A1DCTPP1HSD11B1SMN1; SMN2
SCHEMBL11945042 0.81 MAPT (0.53) MAPTALDH1A1DCTPP1SMN1; SMN2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8232274-B2 Pyridazinone derivatives useful as glucan synthase inhibitors ALBANY MOLECULAR RESEARCH, INC. (US) 2012-07-31 — — US disclosed
US-8232274-B2 Pyridazinone derivatives useful as glucan synthase inhibitors ALBANY MOLECULAR RESEARCH, INC. (US) 2012-07-31 — — US disclosed
US-20090170861-A1 Pyridazinone Derivatives Useful as Glucan Synthase Inhibitors SCHERING CORPORATION AND ALBANY MOLECULAR RESEARCH, INC. 2009-07-02 — — US disclosed
US-20090170861-A1 Pyridazinone Derivatives Useful as Glucan Synthase Inhibitors SCHERING CORPORATION AND ALBANY MOLECULAR RESEARCH, INC. 2009-07-02 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090170861-A1 Pyridazinone Derivatives Useful as Glucan Synthase Inhibitors MAN2A1, GYS2, MANBA MAPT 2295/4885ALDH1A1 2437/4885DCTPP1 625/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback